AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Zenas BioPharma's Obexelimab meets primary endpoint in IgG4-RD flare reduction trial.
ByAinvest
Monday, Jan 5, 2026 7:10 am ET1min read
Obexelimab met the primary endpoint, reducing IgG4-RD flare risk by 56%, and all four key secondary efficacy endpoints. It was well tolerated with no new safety signals. Zenas plans to submit a Biologics License Application to the FDA in Q2 2026 and a Marketing Authorization Application to the EMA in H2 2026. The company will host a conference call today at 8:00 a.m. ET.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc's editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet